Preventing Adverse Drug Events With PatientSite
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00140504|
Recruitment Status : Completed
First Posted : September 1, 2005
Last Update Posted : February 26, 2013
|Condition or disease||Intervention/treatment||Phase|
|Adverse Drug Event||Other: Medcheck message||Not Applicable|
- A drug safety module called MedCheck was developed for PatientSite. This allows physicians to query patients automatically 10 days after they receive a new prescription asking them questions about their new prescription. In this study new enhancements will be tested.
- Participants will be assigned at random to the intervention group or control group. The intervention group will receive a single electronic PatientSite message asking them questions about the new prescription which is then forwarded to their physician. The control group will receive a generic message about medication safety.
- To identify adverse drug events, a telephone survey and medical record review will be conducted of patients in the intervention group and controls.
- This study will run for 12 months.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||800 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||Preventing Adverse Drug Events With PatientSite|
|Study Start Date :||April 2003|
|Actual Primary Completion Date :||December 2004|
|Actual Study Completion Date :||December 2004|
Electronic medication safety queries via PatientSite portal
Other: Medcheck message
Participants selected at random will receive one email message asking them questions about their prescription which will be forwarded to their physician
No Intervention: Usual care
No electronic medication safety messages via PatientSite portal
- To prevent adverse drug events with PatientSite. [ Time Frame: 3 years ]
- Improve patient satisfaction [ Time Frame: 3 years ]
- better utilization of services [ Time Frame: 3 years ]
- improve patient-clinician communication [ Time Frame: 3 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00140504
|United States, Massachusetts|
|Beth Israel Deaconess Medical Center|
|Boston, Massachusetts, United States, 02215|
|Principal Investigator:||Saul N Weingart, MD, PhD||Dana-Farber Cancer Institute|